22 Aug 2019
Posted by Andrew Kantor
Opioid abuse is decreasing dramatically … at least in some states. While the nation as a whole is seeing an 11 percent drop, states that expanded Medicaid are seeing much better numbers, in part because of buprenorphine. (The ACA requires insurers, including Medicaid, to cover medication-assisted addiction treatment.)
In Medicaid-expanding states, buprenorphine prescriptions increased from 40 to 138 per 1,000 enrollees, Urban researchers found. In non-Medicaid-expanding states, they increased from 16 to 41.
Endo Pharmaceuticals (2017 revenue: $3.5 billion) has agreed to pay $10 million* to settle lawsuits from two Ohio counties for its role in the opioid crisis.
Allergan (2018 revenue: $15.8 billion) has agreed to pay $5 million** to those counties for its role.
Migrant children being held in U.S. detention camps won’t be given the flu vaccine this year, even though three have already died from flu-related complications. Concentration with other immigrants makes it easy for infectious diseases to spread, making the problem worse.
A new survey finds that, among the people who can’t afford their diabetes meds, women are more likely than men to skip doses to save money (14.9% compared to 11.6%) but are also slightly more likely to ask for a lower-cost alternative.
Also of note: People over 65 are more likely not to skip their meds than younger folks.
Former smokers are even more likely to suffer from depression and substance abuse than either non-smokers or current smokers.
On the other hand: Quitting smoking cuts cardiovascular risk in as little as five years.
Hetlioz, the anti-jet-lag drug from Vanda Pharmaceuticals, still hasn’t gotten FDA approval, leaving the company “perplexed.”
Imagine a patient comes to you with a painful eyebrow. What advice can you give? Medical News Today has some answers.